Forlong Biotechnology
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Forlong Biotechnology - overview
Established
2019
Location
Suzhou, Jiangsu, China
Primary Industry
Biotechnology
About
Based in Suzhou, China, and founded in 2019, Suzhou Forlong Biotechnology Co. , Ltd. , trading as Forlong Biotechnology, is a clinical-stage biotechnology company focusing on the development of next-generation cytokine drugs. In May 2026, Forlong Biotechnology raised a pre-series B funding led by Fudan Science & Technology Venture Capital.
The company's core pipeline FL115 is an engineered IL-15/IL15Rα-Fbody fusion protein that exerts anti-tumor effects by activating NK cells and memory T cells. In the indication of non-muscle-invasive bladder cancer (NMIBC), it has entered Phase II clinical trials in combination with BCG, and preliminary data show its potential as a biochemical infusion protein (BIC). The company's revenue is generated by developing engineered therapeutic cytokine combinations that target different stages of the cancer-immune cycle to treat cancer. The company will use the latest funding to advance the registration clinical of its blockbuster IO2.
0 cytokine therapy product FL115 and the clinical development stage of FL116, as well as to continuously expand its technology platform and product pipeline.
Current Investors
SND Ventures Group, Renhe Capital, Puhua Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.forlongbiotech.com.cn/
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.